TauGen targets early brain injury biology as CTE concern grows

A new study in former NFL players adds to evidence that chronic traumatic encephalopathy can affect athletes after repeated head impacts, while TauGen is advancing drug candidates aimed at the early biological events that follow traumatic brain injury. The work underscores a major medical gap: CTE still cannot be definitively diagnosed in living patients, and no proven therapy exists to stop or reverse the disease.

Why it matters: - CTE remains one of the clearest long-term risks linked to repetitive head trauma. - The lack of a living diagnosis and a proven treatment leaves patients with only supportive care. - A therapy that can interrupt early injury biology could change how traumatic brain injury and CTE-related disease are managed.

What happened: - A recent study in the British Medical Journal found CTE neuropathology in about one-quarter of deceased former NFL players examined. - Longer football careers were associated with more severe disease. - The investigators said the true prevalence in the studied group could be higher. - TauGen said it is advancing novel drug candidates designed to target early biological processes after repetitive or severe brain injury.

The details: - Previous research has also found CTE neuropathology at autopsy in people with non-professional contact sports exposure and in military veterans exposed to traumatic brain injury. - Those military exposures included blast-related injuries and large-caliber weapons training. - Current clinical management of CTE is largely supportive and focuses on mood and behavioral changes, sleep disturbance, headaches, and pain. - Severe brain trauma and repetitive head impacts can trigger microvascular injury, inflammation, and disruption of normal neuronal and cellular processes. - Those changes may contribute to abnormal tau biology, impaired neuronal function, and progressive neurodegeneration. - Dr. Brandon Lucke-Wold said the biology of CTE appears to begin long before advanced neuropathology is visible at autopsy. - Dr. Lucke-Wold said brain trauma can start vascular, inflammatory, and neuronal changes that may promote abnormal tau accumulation and progressive loss of neuronal function. - Dr. Lucke-Wold also said beta-amyloid may contribute in some patients. - TauGen is developing a portfolio of novel molecules intended to interrupt specific trauma-induced neuropathological pathways after severe or repetitive head injury. - TauGen CEO Henry Chilton said the company is trying to intervene as close to the initiating injury as possible, before downstream pathological processes become established. - Chilton said TauGen’s initial development program includes a nasally administered formulation for use at or near the time of traumatic injury. - Chilton said the company is also developing other formulations intended to provide options during the period when injury-related biological processes are occurring. - TauGen LLC is an early-stage drug development company closely affiliated with CereMark Pharma, LLC. - TauGen said it is focused on targeted therapies for biological mechanisms associated with traumatic brain injury and CTE-related neuropathology.

Between the lines: - The study findings reinforce how much of CTE medicine still centers on postmortem diagnosis rather than early intervention. - TauGen is positioning its pipeline around a narrow but potentially important window: the hours and days after injury, before long-term damage becomes fixed. - The approach reflects a broader shift in neurotrauma research toward targeting upstream biology instead of waiting for symptoms to worsen.

What's next: - TauGen’s next milestone will be advancing its early-stage drug candidates through development. - The key test for the field will be whether therapies aimed at early trauma biology can meaningfully alter the course of CTE-related disease.

The bottom line: - The new findings add urgency to CTE research, and TauGen is betting that earlier, mechanism-based treatment may be the best path forward.